Gaviscon Advance Oral Suspension

Gaviscon Advance is an antacid and alginate-based treatment designed to provide relief from gastroesophageal reflux, heartburn, and acid indigestion. It works by creating a protective physical barrier on top of the stomach contents to prevent reflux into the esophagus.

The Gaviscon formulation was originally developed in 1964 in Sweden by Ferrosan and subsequently commercialized internationally by Reckitt & Colman (now Reckitt Benckiser). In Europe and most global markets, including Italy, Gaviscon is owned and manufactured by Reckitt Benckiser Group plc (Reckitt), a British multinational consumer goods and healthcare corporation headquartered in Slough, England. The European products are primarily manufactured at Reckitt's production facility in Hull, United Kingdom.

Note that in the United States and Canada, the rights to the Gaviscon trademark were acquired separately by GlaxoSmithKline (now Haleon), which distributes an aluminum hydroxide-based formulation under the same brand name.